Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies

SelfRugger · 2026-02-14T08:25:02+00:00

Novo Nordisk has initiated a patent lawsuit against Hims & Hers for selling compounded versions of its weight-loss drug Wegovy, marking its first legal action in the U.S. against such competitors amid growing telehealth expansion in the market.

SelfRugger

2026-02-14 08:25:02

Abstract generation in progress

Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies

Reuters Videos

Wed, February 11, 2026 at 12:23 AM GMT+9

In this video:

NVO

+1.83%

HIMS

-4.89%

STORY: Novo Nordisk filed a patent lawsuit against Hims & Hers on Monday.It marks a new front in the Danish drugmaker’s campaign against companies selling compounded versions of its blockbuster weight-loss drug Wegovy.The case is Novo’s first U.S. patent infringement lawsuit against a compounder over Wegovy.And comes as large telehealth companies have expanded rapidly into the weight-loss drug market.Particularly after the U.S. Food and Drug Administration determined that the drug’s active ingredient semaglutide is no longer in short supply.Novo’s lawsuit follows Hims’ launch on Thursday of a $49 compounded version of Wegovy.And then a quick retreat after the FDA announced it would take action against the company last week.In a statement, Hims said the lawsuit, quote, “assaults a well-established, vital component of US pharmacy practice”. Adding that it has, quote, “improved patient care for everything from obesity to infertility to cancer.”Novo’s complaint did not specify how much the company was seeking in damages,But its general counsel told Reuters it was a “very significant amount.”

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.